Who Paid My Doc
Gilbert Alligood
Adolescent Medicine Middlesex, NC Medical Doctor
NPI 1588644157 CMS profile 253380
7540 Middlesex Corporate Pkwy, Middlesex, NC 27557
General payments
$12
Research payments
$0
Ownership & investment interest
$0
Through program year 2019, Gilbert Alligood of Middlesex, NC is reported in the CMS Open Payments database as having received $12 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $12 | 1 |
Beside peers
- Gilbert Alligood
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Gilbert Alligood were reported at $0. Among 113 Adolescent Medicine profiles paid that year, the median was $165 and the middle half received between $61 and $402.
Show as a table
| Year | Gilbert Alligood | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $12 | $151 | $36–$708 | $163 |
| 2020 | $0 | $123 | $24–$337 | $114 |
| 2021 | $0 | $155 | $54–$620 | $132 |
| 2022 | $0 | $158 | $50–$556 | $149 |
| 2023 | $0 | $170 | $52–$612 | $160 |
| 2024 | $0 | $182 | $65–$431 | $164 |
| 2025 | $0 | $165 | $61–$402 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 152 drugsPart D claims
10,431
Drug cost
$727,406
Branded share of claims
20.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 143 | $128,986 | |
| Ozempic Semaglutide | Brand | 91 | $115,321 | |
| Jardiance Empagliflozin | Brand | 124 | $112,110 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 57 | $38,942 | |
| Trulicity Dulaglutide | Brand | 36 | $38,816 | |
| Linzess Linaclotide | Brand | 40 | $29,590 | |
| Mounjaro Tirzepatide | Brand | 22 | $22,410 | |
| Tradjenta Linagliptin | Brand | 15 | $19,970 | |
| Myrbetriq Mirabegron | Brand | 40 | $18,042 | |
| Humulin R U-500 Kwikpen Insulin Regular, Human | Brand | 20 | $17,768 |
The 10 drugs with the highest cost, of 152 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 48 billing codesPaid by Medicare
$53,163
Medicare patients
242
Services billed
1,093
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 32% | |
| Ischemic heart disease | 24% | |
| COPD | 20% | |
| Diabetes | 19% | |
| Atrial fibrillation | 17% | |
| Cancer | 15% | |
| Chronic kidney disease | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 70 | 70 | $5,564 |
| Sarscv2 vac 30mcg trs-suc im 91320 | Office | 13 | 13 | $1,986 |
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90686 | Office | 12 | 12 | $263 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adolescent Medicine in North Carolina
Related records
Adolescent Medicine in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.